Queensland Treasurer Declares Coal Plants ‘Will Remain Open' as Long as Economically Needed
Queensland LNP Treasurer David Janetzki has backed the continued use of coal in powering the state.
The bold statement comes amid bids from energy industry stakeholders for less red tape and environmental restrictions to develop energy sources in Australia.
'[Coal-fired power stations] will remain open as long as it is economically sensible and systematically needed, not [closed on] an arbitrary date to fill a headline for a day,' Janetzki told the Australian Energy Producers conference, in comments obtained by AAP.
'While electrification is a suitable alternative to some of the fuels we currently use, key industries such as heavy transport, mining, construction, shipping, agriculture, and aviation will be impossible to electrify.'
The conference was held in Brisbane on May 27.
A day later, the LNP Crisafulli government opened up nine sites for gas exploration and development, accepting tenders from May 29.
Turbine Turnaround
The comments from Janetzki come barely a day after
Related Stories
5/23/2024
12/15/2023
The decision not to allow the 88-turbine wind farm to go ahead was based on submissions from the public, where 473 out of 550 did not support the plan going ahead.
It was subsequently found the proposal did not meet the requirements of the government's new planning laws, which ensure renewable energy projects are assessed by the same approval processes for other resource projects.
'Queenslanders deserve to have a say on any major development in their local community, which is why our government introduced new nation-leading laws to give them a voice on issues that impact that future of their towns,' Minister for Infrastructure Jarrod Bleijie said in a statement.
Calls for Less Restrictions on Traditional Energies
During the conference, former Ambassador to the United States Joe Hockey and Woodside CEO Meg O'Neill also called for less restrictions on traditional energy sources.
'With the new federal parliament elected, it is an opportunity to finally cut red and green tape to simplify and streamline Australia's approval system,' O'Neill said, also urging support for mining exploration across Australia.
Hockey, who appeared via tele-conference from Singapore, said Australia needed to identify more gas and oil opportunities.
'We need to get back to some basic principles that if you have less regulation, if you have less onerous taxes and less tax then you are more likely to grow your economy,' he said.
On May 28, Environment Minister Murray Watt announced Woodside's plans for expanding the North West Shelf gas processing plant in Western Australia beyond 2030
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 hours ago
- Yahoo
‘Heartbreaking': Gas extension decision slammed
Faith leaders say they are 'deeply troubled' by the Federal Government's decision to approve the extension of the North West Shelf gas processing facility to 2070. On Wednesday, Labor approved a 40-year extension of the country's largest gas plant. While Environment Minister Murray Watt's decision to grant the approval for Woodside's North West Shelf extension in Western Australia's Pilbara has been praised by industry and unions, others have condemned it due to the threat to the Murujuga cultural heritage. President of the Uniting Church in Australia, Rev Charissa Suli told reporters in Perth on Sunday, she is 'profoundly disappointed' about the approval of the North West Shelf gas processing facility. 'As a daughter of the Pacific, I have witnessed first-hand the devastating impacts of climate change on culturally rich but environmentally vulnerable nations in our region,' she said. 'These nations — many of which are home to Uniting Church partners within the Asia-Pacific — contribute the least to global emissions yet suffer the greatest consequences. 'Why then is approval granted to an old, polluting facility to continue emitting vast volumes of climate damaging emissions of a magnitude many times greater than the emissions of all the Pacific nations? This is not loving thy neighbour.' Rev Mitchell Garlett from the Uniting Aboriginal & Islander Christian Congress added he is 'very disappointed' that the decision was made without 'close consultation with the relevant Traditional Owners'. 'The connection we feel to Country is not just a physical thing but a spiritual connection that is deeper than what we see with our eyes,' he said. 'It is heartbreaking that reconciliation is spoken of but our brothers and sisters voices are not being heard, and the land continues to suffer for so-called progress.' Rev Dr Ian Tozer added they are 'deeply concerned' by the threat to First Nations cultural heritage sites, including 60,000-year-old priceless petroglyphs at the World Heritage nominated Murujuga rock art site. 'It is vital that these ancient sites, so precious to Australia's First Peoples and to our history, are not further damaged by industry,' he said. Meanwhile, Woodside has said the approval would support thousands of jobs and supply affordable energy to Western Australia. The project has supplied 6000 petajoules of domestic gas, powering homes and industry in Western Australia with enough energy to power homes in a city the size of Perth for approximately 175 years, the company said. Environmental groups estimate the project will produce 4.3 billion tons of greenhouse gas emissions over its lifetime.
Hamilton Spectator
2 days ago
- Hamilton Spectator
Council awards $2.76 million contract for Skyline Drive watermain replacement
Gibsons council unanimously approved a contract award for water main replacement and road paving on Skyline Drive during a May 27 special meeting of council. William Wallace, Gibsons director of finance, highlighted that the project, valued at up to $2.76 million, is the first major infrastructure project since COVID-19 that hasn't required additional funding beyond the original budget. The contract was awarded following a competitive bidding process that received three submissions. One bid stood out due to its pricing and overall quality, prompting staff to recommend the award said Trevor Rutley, Gibsons director of infrastructure services. The work will focus on the highest-priority section of Skyline Drive, where two substantial water main breaks occurred within recent years. The targeted area also includes associated side streets like Avalon Drive, Shoal Lookout, and Allison Way, which have been identified in the town's water system strategic plan as requiring attention due to condition and capacity issues. Rutley explained that the current scope represents approximately half of the total water main replacement needed on the bluff area. The remaining work, estimated at $5-6 million, would require additional funding in future years. Council members emphasized the importance of clear communication with residents about project boundaries, particularly given that some properties will receive upgrades while neighbouring homes may not be included in this phase. The project is funded through an alternative approval process (AAP) authorizing the Town to borrow funds to complete the Skyline Drive water main project, which closed on July 3, 2024. The AAP secured $2,185,000 for water main replacement (Water) and $555,000 for paving (General). Construction is expected to be completed before winter weather conditions halt paving operations. Jordan Copp is the Coast Reporter's civic and Indigenous affairs reporter. This reporting beat is made possible by the Local Journalism Initiative . Words missing in article? Your adblocker might be preventing hyperlinked text from appearing. Error! Sorry, there was an error processing your request. There was a problem with the recaptcha. Please try again. You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy . This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply. Want more of the latest from us? Sign up for more at our newsletter page .
Yahoo
2 days ago
- Yahoo
Myeloid Therapeutics Unveils First-in-Human In Vivo mRNA CAR Data, Marking a Breakthrough in RNA-Based Immuno-Oncology at the 2025 ASCO Annual Meeting
– MT-302 and MT-303 embody the first clinical applications of in vivo mRNA CAR therapies administered systemically – – Initial translational results support proof-of-mechanism with immune reprogramming resulting in tumor penetration and pro-inflammatory alteration in the TME – CAMBRIDGE, Mass., May 30, 2025 /PRNewswire/ -- Myeloid Therapeutics, Inc. ("Myeloid"), a clinical-stage immunology company advancing RNA therapeutics to conquer cancer, today announced it will present two posters at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago taking place from May 30 – June 3, 2025. The presentations will highlight the clinical trial design for MT-303 and preliminary translational findings for MT-302 – the company's lead in vivo mRNA CAR therapies, which together signify a key milestone in the field of RNA-based immuno-oncology. "Our presentations at ASCO demonstrate the clinical translation of our proprietary mRNA-LNP platform for in vivo immune cell engineering," said Daniel Getts, PhD, CEO and Co-founder of Myeloid Therapeutics. "With MT-302 and MT-303, we are pushing beyond the limits of traditional CAR therapies—removing the need for often complicated ex vivo manipulation while delivering potent, tumor-specific immune activation in patients with advanced solid tumors." "These data show that we can deliver repeated doses of LNP-mRNA in patients demonstrating that CAR-programmed myeloid cells can penetrate solid tumors and alter the tumor microenvironment (TME), which opens up multiple avenues for potential clinical benefit moving forward," said Matt Maurer, MD, Chief Medical Officer of Myeloid Therapeutics. "The results offer early validation of Myeloid's platform technologies, and could ultimately change how solid tumors are treated, offering patients a more accessible, potentially more tolerable, and highly targeted therapy option in the future without the burdens associated with traditional cell therapies." MT-302: TROP2-Targeted mRNA CAR Therapy in Advanced Epithelial Tumors MT-302 is the first intravenously delivered mRNA-based CAR therapy to enter clinical trials. It uses synthetic mRNA encapsulated in lipid nanoparticles (LNPs) to reprogram circulating immune cells in vivo to express a TROP2-targeted CAR. Poster Board: 238 Title: First-in-human mRNA CAR Therapy: Correlative Biomarker analysis from the MT-302 Phase 1 Study Targeting TROP2 in Patients with Advanced Epithelial Tumors Lead Author: Dr. Charlotte Lemach, MBBS Session Date & Time: June 2, 2025 | 1:30 PM–4:30 PM CDT Location: Hall A, McCormick Place, Chicago Key MT-302 Findings Include: Immune Activation: Single-cell RNA sequencing demonstrated selective CAR expression in myeloid cells and increased pro-inflammatory gene signatures across tumor types. Target Engagement: Pharmacodynamic markers confirmed successful delivery and CAR expression following systemic administration. Continued dose escalation: Dose escalation continues with an optimized liner mRNA based on preclinical demonstration of expression beyond 12 days. MT-303: GPC3-Targeted mRNA CAR Therapy in Hepatocellular Carcinoma MT-303 is an innovative in vivo CAR therapy specifically designed to reprogram Fc receptor gamma chain-expressing myeloid cells to recognize and destroy GPC3+ tumor cells following intravenous mRNA-LNP administration. Poster Board: 499b Title: A First-in-Human Study of MT-303, an Innovative In Vivo mRNA CAR Therapy Targeting GPC3 in Adults with Hepatocellular Carcinoma Lead Author: Dr. Timothy Humphries, Linear Clinical Research Session Date & Time: May 31, 2025 | 9:00 AM-12:00 PM CDT Location: Hall A, McCormick Place, Chicago MT-303 Clinical Trial Highlights: Design: Ongoing multicenter, open-label Phase 1 trial in advanced solid tumors expressing GPC3 (including HCC) employing a Bayesian Optimal Interval (BOIN) dose escalation. Mechanism: mRNA encodes a GPC3-targeted CAR construct driven by CD89, restricting expression to myeloid cells. Myeloid expects to share additional clinical translational data at an upcoming medical meeting upon completion of the Phase 1 studies of MT-302 and MT-303. About MT-302 MT-302 is a first-in-class, TROP2-FcA-LNP targeting TROP2, which is overexpressed in many epithelial tumors and corresponds with low expression in healthy tissues. MT-302 has demonstrated promising preclinical results to date, including robust expression in myeloid cells and a favorable safety profile in rodents and non-human primates. Unlike other therapies, MT-302 brings the potential advantages of eliciting a full immune response by also presenting tumor neoantigen to stimulate T cells. MT-302 is Myeloid's first in vivo CAR clinical program that further builds on the company's innovative approach to cancer treatment through immune cell programming. About MT-303 MT-303 is a first-in-class, GPC3-FcA-LNP targeting glypican-3 (GPC3), which is overexpressed in most human hepatocellular carcinomas (HCCs) and exhibits limited expression in healthy tissues. MT-303 has demonstrated promising preclinical results to date, including robust expression in myeloid cells and a favorable safety profile in rodents and non-human primates. Unlike other therapies, MT-303 brings the potential advantages of eliciting a full immune response by also presenting tumor neoantigen to stimulate T cells. MT-303 is Myeloid's second in vivo CAR clinical program that further builds on the company's innovative approach to cancer treatment through immune cell programming. About Myeloid Therapeutics Myeloid Therapeutics is a clinical stage immunology company, engineering cutting-edge RNA technology to program immune cells to combat cancer and other deadly diseases. Myeloid is headquartered in Cambridge, MA. For additional information, please visit, and follow us on LinkedIn and X/Twitter. For collaborative interests, write to partnering@ Investor ContactBrian Korb, Astr Media ContactPeg Rusconi, Deerfield View original content to download multimedia: SOURCE Myeloid Therapeutics, Inc Sign in to access your portfolio
